Cara Therapeutics (CARA) 5.38 $CARA Cara Therap
Post# of 273258
Posted On: 09/02/2016 3:16:50 AM
Cara Therapeutics (CARA) 5.38 $CARA
Cara Therapeutics to Sponsor Symposium and Present Posters at PAINWeek
GlobeNewswire - Thu Sep 01, 7:00AM CDT
-- Pain experts to discuss developments in kappa opioid receptor agonists and the future of pain management
CARA: 5.38 (-0.04)
How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 5.38 (-0.04), PGNX: 6.14 (-0.14), PPHM: 0.36 (unch), AGIO: 36.74 (-0.10)
Diversity of the Legal and Medical Marijuana Markets
PR Newswire - Wed Aug 24, 11:00AM CDT
Legal U.S. marijuana sales reached $5.4 billion for 2015, which represents an increase of 17.4 percent from the $4.6 billion in 2014 according to ArcView Market Research. This year, even a bigger jump in sales is expected. As a result, more companies across the entire industry are trying their luck. What is more surprising is just how diverse the Cannabis industry is becoming. Freedom Leaf Inc. (OTC: FRLF), Medical Marijuana Inc (OTC: MJNA), Terra Tech Corp (OTCQX: TRTC), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE)
CARA: 5.38 (-0.04), ZYNE: 8.57 (+0.09)
The Growth of the Legal and Medical Marijuana Markets
PR Newswire - Tue Aug 23, 8:57AM CDT
The legal marijuana market in the United States is projected to grow substantially in 2016. A recent report by New Frontier and ArcView Market Research projected the marijuana market in the United States to grow to $7.1 billion in 2016, which represents a 26% growth comparing to 2015. Veritas Pharma Inc. (OTC: VRTHF), Cara Therapeutics Inc (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Terra Tech Corp. (TRTC), GW Pharmaceuticals PLC (NASDAQ: GWPH)
CARA: 5.38 (-0.04), GWPH: 82.28 (+0.53), ZYNE: 8.57 (+0.09)
Cara Therapeutics to Webcast Presentation at Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Fri Aug 05, 7:00AM CDT
Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Canaccord Genuity 36 Annual Growth Conference on Thursday, August 11, 2016, at 12:30 p.m. ET in Boston.
CARA: 5.38 (-0.04)
Cara Therapeutics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:03PM CDT
- Resumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative pain -
CARA: 5.38 (-0.04)
Cara Therapeutics to Announce Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 7:01AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2016, at 4:30 p.m. ET to report second quarter 2016 financial results and provide a corporate update.
CARA: 5.38 (-0.04)
Cara Therapeutics to Present Preclinical Data at June Medical Meetings
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the presentation of preclinical data, including one late-breaking abstract, at the International Study Group Investigating Drugs as Reinforcers (to be held June 11, 2016) and the College on Problems of Drug Dependence 78 Annual Scientific Meeting (to be held June 11-16, 2016), both of which will take place in Palm Springs, California.
CARA: 5.38 (-0.04)
NTRR: Cannabis' Better-than-Expected Tax Revenues Could Speed Legalization Efforts
ACCESSWIRE - Wed Jun 08, 4:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.
XXII: 1.03 (+0.01), CARA: 5.38 (-0.04), GWPH: 82.28 (+0.53)
Cara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has resumed patient recruitment after the U.S. Food and Drug Administration (FDA) removed a clinical hold on its CLIN3001 adaptive Phase 3 trial of I.V. CR845 for postoperative pain.
CARA: 5.38 (-0.04)
Biotech Industry's Stocks Get Research Review
ACCESSWIRE - Fri Jun 03, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 3, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Biotechnology industry. Companies recently under review include XOMA, Vericel, Cara Therapeutics, and Regulus Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
CARA: 5.38 (-0.04), VCEL: 2.23 (-0.01), RGLS: 3.16 (-0.01), XOMA: 0.56 (-0.01)
NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites
ACCESSWIRE - Thu Jun 02, 4:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.
XXII: 1.03 (+0.01), CARA: 5.38 (-0.04), GWPH: 82.28 (+0.53)
Cannabis & Legal Marijuana Sector Continues To See Steady Growth As Companies Launch Newest Innovative Products; Company to Develop First Ever MMJ Plant to Paper Product
PR Newswire - Wed Jun 01, 7:30AM CDT
As legal & medical marijuana uses evolves and becomes more accepted in US society, companies continue to push the industry forward with increased research and the development of new products and services. With Legal Marijuana Sales expected to top $20 Billion within five years, innovative and emerging MMJ/Cannabis companies in the sector race to develop newest products for states currently online with production and sales.
CARA: 5.38 (-0.04), XXII: 1.03 (+0.01)
Cara Therapeutics Selected to Present at the 2016 International Conference on Opioids
GlobeNewswire - Tue May 31, 7:00AM CDT
-- Leading experts to discuss unique pharmacology of peripherally selective opioids to manage chronic and acute pain during opening session
CARA: 5.38 (-0.04)
Cara reports 1Q loss
Automated Insights - Thu May 05, 5:14PM CDT
SHELTON, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Thursday reported a loss of $10.7 million in its first quarter.
CARA: 5.38 (-0.04)
Cara Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:01PM CDT
- Conference call today at 4:30 p.m. ET -
CARA: 5.38 (-0.04)
Cara Therapeutics to Sponsor Symposium at American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Wed May 04, 7:00AM CDT
-- Pain experts to discuss kappa opioid receptor agonists as alternative to standard mu opioid agonists
CARA: 5.38 (-0.04)
Cara Therapeutics to Announce First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Thu Apr 28, 3:30PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, May 5, 2016, at 4:30 p.m. ET to report first quarter 2016 financial results and provide a corporate update.
CARA: 5.38 (-0.04)
Don't Get Smoked by These Pot Stocks on 4/20
David Bartosiak - Zacks Investment Research - Wed Apr 20, 3:45PM CDT
Pot is still illegal at the Federal level but there are some medicinal marijuana companies worth looking at
CARA: 5.38 (-0.04), JNJ: 119.08 (-0.26), INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53), YUM: 90.76 (+0.05), PEP: 107.29 (+0.54)
This Biotech Is Up 300 In Two Months
ACCESSWIRE - Wed Apr 20, 9:45AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 20, 2016 / Sean Parker just made an incredible donation, and thus created the "Parker Institute for Cancer Immunotherapy."
CARA: 5.38 (-0.04)
Cara Therapeutics to Sponsor Symposium and Present Posters at PAINWeek
GlobeNewswire - Thu Sep 01, 7:00AM CDT
-- Pain experts to discuss developments in kappa opioid receptor agonists and the future of pain management
CARA: 5.38 (-0.04)
How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 5.38 (-0.04), PGNX: 6.14 (-0.14), PPHM: 0.36 (unch), AGIO: 36.74 (-0.10)
Diversity of the Legal and Medical Marijuana Markets
PR Newswire - Wed Aug 24, 11:00AM CDT
Legal U.S. marijuana sales reached $5.4 billion for 2015, which represents an increase of 17.4 percent from the $4.6 billion in 2014 according to ArcView Market Research. This year, even a bigger jump in sales is expected. As a result, more companies across the entire industry are trying their luck. What is more surprising is just how diverse the Cannabis industry is becoming. Freedom Leaf Inc. (OTC: FRLF), Medical Marijuana Inc (OTC: MJNA), Terra Tech Corp (OTCQX: TRTC), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE)
CARA: 5.38 (-0.04), ZYNE: 8.57 (+0.09)
The Growth of the Legal and Medical Marijuana Markets
PR Newswire - Tue Aug 23, 8:57AM CDT
The legal marijuana market in the United States is projected to grow substantially in 2016. A recent report by New Frontier and ArcView Market Research projected the marijuana market in the United States to grow to $7.1 billion in 2016, which represents a 26% growth comparing to 2015. Veritas Pharma Inc. (OTC: VRTHF), Cara Therapeutics Inc (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Terra Tech Corp. (TRTC), GW Pharmaceuticals PLC (NASDAQ: GWPH)
CARA: 5.38 (-0.04), GWPH: 82.28 (+0.53), ZYNE: 8.57 (+0.09)
Cara Therapeutics to Webcast Presentation at Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Fri Aug 05, 7:00AM CDT
Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Canaccord Genuity 36 Annual Growth Conference on Thursday, August 11, 2016, at 12:30 p.m. ET in Boston.
CARA: 5.38 (-0.04)
Cara Therapeutics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:03PM CDT
- Resumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative pain -
CARA: 5.38 (-0.04)
Cara Therapeutics to Announce Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 7:01AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2016, at 4:30 p.m. ET to report second quarter 2016 financial results and provide a corporate update.
CARA: 5.38 (-0.04)
Cara Therapeutics to Present Preclinical Data at June Medical Meetings
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the presentation of preclinical data, including one late-breaking abstract, at the International Study Group Investigating Drugs as Reinforcers (to be held June 11, 2016) and the College on Problems of Drug Dependence 78 Annual Scientific Meeting (to be held June 11-16, 2016), both of which will take place in Palm Springs, California.
CARA: 5.38 (-0.04)
NTRR: Cannabis' Better-than-Expected Tax Revenues Could Speed Legalization Efforts
ACCESSWIRE - Wed Jun 08, 4:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.
XXII: 1.03 (+0.01), CARA: 5.38 (-0.04), GWPH: 82.28 (+0.53)
Cara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has resumed patient recruitment after the U.S. Food and Drug Administration (FDA) removed a clinical hold on its CLIN3001 adaptive Phase 3 trial of I.V. CR845 for postoperative pain.
CARA: 5.38 (-0.04)
Biotech Industry's Stocks Get Research Review
ACCESSWIRE - Fri Jun 03, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 3, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Biotechnology industry. Companies recently under review include XOMA, Vericel, Cara Therapeutics, and Regulus Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
CARA: 5.38 (-0.04), VCEL: 2.23 (-0.01), RGLS: 3.16 (-0.01), XOMA: 0.56 (-0.01)
NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites
ACCESSWIRE - Thu Jun 02, 4:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.
XXII: 1.03 (+0.01), CARA: 5.38 (-0.04), GWPH: 82.28 (+0.53)
Cannabis & Legal Marijuana Sector Continues To See Steady Growth As Companies Launch Newest Innovative Products; Company to Develop First Ever MMJ Plant to Paper Product
PR Newswire - Wed Jun 01, 7:30AM CDT
As legal & medical marijuana uses evolves and becomes more accepted in US society, companies continue to push the industry forward with increased research and the development of new products and services. With Legal Marijuana Sales expected to top $20 Billion within five years, innovative and emerging MMJ/Cannabis companies in the sector race to develop newest products for states currently online with production and sales.
CARA: 5.38 (-0.04), XXII: 1.03 (+0.01)
Cara Therapeutics Selected to Present at the 2016 International Conference on Opioids
GlobeNewswire - Tue May 31, 7:00AM CDT
-- Leading experts to discuss unique pharmacology of peripherally selective opioids to manage chronic and acute pain during opening session
CARA: 5.38 (-0.04)
Cara reports 1Q loss
Automated Insights - Thu May 05, 5:14PM CDT
SHELTON, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Thursday reported a loss of $10.7 million in its first quarter.
CARA: 5.38 (-0.04)
Cara Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:01PM CDT
- Conference call today at 4:30 p.m. ET -
CARA: 5.38 (-0.04)
Cara Therapeutics to Sponsor Symposium at American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Wed May 04, 7:00AM CDT
-- Pain experts to discuss kappa opioid receptor agonists as alternative to standard mu opioid agonists
CARA: 5.38 (-0.04)
Cara Therapeutics to Announce First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Thu Apr 28, 3:30PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, May 5, 2016, at 4:30 p.m. ET to report first quarter 2016 financial results and provide a corporate update.
CARA: 5.38 (-0.04)
Don't Get Smoked by These Pot Stocks on 4/20
David Bartosiak - Zacks Investment Research - Wed Apr 20, 3:45PM CDT
Pot is still illegal at the Federal level but there are some medicinal marijuana companies worth looking at
CARA: 5.38 (-0.04), JNJ: 119.08 (-0.26), INSY: 14.36 (+0.09), GWPH: 82.28 (+0.53), YUM: 90.76 (+0.05), PEP: 107.29 (+0.54)
This Biotech Is Up 300 In Two Months
ACCESSWIRE - Wed Apr 20, 9:45AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 20, 2016 / Sean Parker just made an incredible donation, and thus created the "Parker Institute for Cancer Immunotherapy."
CARA: 5.38 (-0.04)
(0)
(0)Scroll down for more posts ▼